Insmed Change in fair value of contingent consideration remained flat by 0.0% to -1.1% in Q4 2025 compared to the prior quarter. Year-over-year, this metric declined by 110.0%, from -0.5% to -1.1%.
Reflects tax accounting volatility stemming from acquisition-related liabilities rather than core operational performance.
Captures the impact of revaluing contingent consideration liabilities on the company's effective tax rate. This adjustme...
Common in biopharma companies with complex acquisition structures and milestone-based payment obligations.
other_effective_income_tax_rate_reconciliation_change_in_330e1b| FY'22 | FY'23 | FY'24 | FY'25 | |
|---|---|---|---|---|
| Value | 0% | 0% | -2% | -4.2% |
| YoY Change | — | — | — | -110.0% |